Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Alzheimer disease pathogenesis involves amyloid-β (Aβ) peptide aggregation, particularly soluble Aβ1-42 oligomers.
• Cellular prion protein (PrP(C)) binds Aβ oligomers, mediating neurotoxicity.
• Physiologically released N-terminal fragment of PrP(C) shows protective effects against Aβ neurotoxicity.

Purpose of the Study:

• To investigate the effect of soluble prion protein and its N-terminal fragment on Aβ1-42 aggregation and toxicity.
• To elucidate the molecular mechanisms underlying the interaction between prion protein and Aβ1-42.

Main Methods:

• Studied the aggregation pathway of Aβ1-42 using soluble prion protein and its N-terminal fragment.
• Assessed Aβ1-42 toxicity in neuronal cell cultures.
• Investigated the effect on amyloid fibril formation and spherical oligomerization.

Main Results:

• Soluble prion protein and its N-terminal fragment significantly inhibit Aβ1-42 assembly into amyloid fibrils.
• Prion protein prevents the formation of spherical oligomers during Aβ fibrillogenesis.
• Prion protein acts as a potent inhibitor of Aβ1-42-induced neurotoxicity in cell culture.

Conclusions:

• Soluble prion protein modulates Aβ1-42 aggregation, preventing toxic oligomer formation.
• Findings provide a molecular basis for the protective role of PrP(C) fragments against Aβ neurotoxicity.
• Suggests a novel therapeutic approach for Alzheimer disease targeting prion protein-Aβ interactions.